Relevance of Plasma Matrix Metalloproteinase-9 for Bronchiolitis Obliterans Syndrome after Allogeneic Hematopoietic Cell Transplantation

Yoshihiro Inamoto, Paul J. Martin, Lynn E. Onstad, Guang Shing Cheng, Kirsten M. Williams, Iskra Pusic, Vincent T. Ho, Mukta Arora, Joseph Pidala, Mary E.D. Flowers, Ted A. Gooley, Richard L. Lawler, John A. Hansen, Stephanie J. Lee

Research output: Contribution to journalArticlepeer-review

Abstract

Bronchiolitis obliterans syndrome (BOS) is a highly morbid form of chronic graft-versus-host disease (GVHD) after allogeneic hematopoietic cell transplantation (HCT). Several plasma proteins have been identified as biomarkers for BOS after lung transplantation. The relevance of these biomarkers in BOS patients after allogeneic HCT has not been examined. We hypothesized that biomarkers associated with BOS after lung transplantation are also associated with BOS after allogeneic HCT. We tested plasma samples from 33 adult HCT patients who participated in a phase II multicenter study of fluticasone, azithromycin, and montelukast (FAM) treatment for new-onset BOS (NCT01307462), and matched control samples of HCT patients who had non-BOS chronic GVHD (n = 31) and those who never experienced chronic GVHD (n = 29) (NCT00637689 and NCT01902576). Candidate biomarkers included matrix metalloproteinase-9 (MMP-9), MMP-3, and chitinase-3-like-1 glycoprotein (YKL-40). MMP-9 concentrations were higher in the patients with BOS compared with those with non-BOS chronic GVHD (P = .04) or no chronic GVHD (P < .001). MMP-3 concentrations were higher in patients with BOS (P < .001) or non-BOS chronic GVHD (P < .001) compared with those with no chronic GVHD. YKL-40 concentrations did not differ statistically among the 3 groups. MMP-9 concentrations before starting FAM therapy were higher in patients who experienced treatment failure within 6 months compared with those with treatment success (P = .006), whereas MMP-3 or YKL-40 concentrations did not differ statistically between these 2 groups. Patients with an MMP-9 concentration ≥200,000 pg/mL before starting FAM therapy had worse overall survival compared with those with lower MMP-9 concentrations. Our data suggest that plasma MMP-9 concentration could serve as a relevant biomarker at diagnosis of BOS after allogeneic HCT for prognostication of survival and for prediction of treatment response. Further validation is needed to confirm our findings.

Original languageEnglish (US)
JournalTransplantation and Cellular Therapy
Volume27
Issue number9
DOIs
StatePublished - Sep 1 2021

Bibliographical note

Funding Information:
We thank all members of the Chronic GVHD Consortium (U54 CA163438), which was funded as part of the National Center for Advancing Translational Sciences (NCATS) Rare Diseases Clinical Research Network (RDCRN). The RDCRN is an initiative of the NCATS Office of Rare Disease Research, funded through collaboration between NCATS and the National Cancer Institute. Financial disclosure: This study was supported by grants from the National Cancer Institute (CA118953 and CA163438) and the Japan Society for the Promotion of Science (18K08345). Conflict of interest statement: Y.I. reports receiving personal fees from Novartis, Janssen, and Meiji Seika Pharma. P.J.M. reports receiving personal fees from Pfizer, the Pediatric Transplantation and Cellular Therapy Consortium, Genentech, Pharmacyclics, Neovii, Enlivex Therapeutics, Mesoblast, Rigel, Talaris, Janssen, and the Mount Sinai School of Medicine; nonfinancial support from Janssen, and others from AbGenomics (now AltruBio). S.J.L. reports receiving grants from Amgen, AstraZeneca, Incyte, Kadmon, Novartis, Pfizer, Syndax, and Takeda and serving on a steering committee for Incyte. The other authors have no conflicts of interest to report. Authorship statement: Y.I. P.J.M. J.A.H. and S.J.L. designed the study; Y.I. L.E.O. and T.A.G. performed the statistical analysis; G.S.C. K.M.W. I.P. V.T.H. M.A. J.P. and M.E.D.F. collected samples and data; R.L.L. performed experiments; and all authors wrote and critically revised the manuscript for important intellectual content and approved the manuscript for publication. Financial disclosure: See Acknowledgments on page XXX.

Funding Information:
Financial disclosure: This study was supported by grants from the National Cancer Institute ( CA118953 and CA163438 ) and the Japan Society for the Promotion of Science ( 18K08345 ).

Publisher Copyright:
© 2021 The American Society for Transplantation and Cellular Therapy

Keywords

  • Allogeneic hematopoietic cell transplantation
  • Bronchiolitis obliterans
  • Chitinase-3-like-1 glycoprotein
  • Matrix metalloproteinase-3
  • Matrix metalloproteinase-9
  • Hematopoietic Stem Cell Transplantation/adverse effects
  • Lung Transplantation
  • Humans
  • Bronchiolitis Obliterans/etiology
  • Graft vs Host Disease
  • Matrix Metalloproteinase 9

PubMed: MeSH publication types

  • Research Support, Non-U.S. Gov't
  • Multicenter Study
  • Journal Article
  • Research Support, N.I.H., Extramural

Fingerprint

Dive into the research topics of 'Relevance of Plasma Matrix Metalloproteinase-9 for Bronchiolitis Obliterans Syndrome after Allogeneic Hematopoietic Cell Transplantation'. Together they form a unique fingerprint.

Cite this